As part of the deal, Lee’s has secured an exclusive license and right from Abiogen to register, import, market, distribute and sell the Cholecalciferol finished products such as oral drops, oral solution and solution for injection, to prevent and treat vitamin D deficiency.
Abiogen president and CEO Dr Massimo Di Martino said the company is happy to extend its strategic collaboration to valorize Lee’s capacities in Hong Kong, China and other countries.
"Deficiency of vitamin D is a Global Silent Epidemic. We have the means to address this threat and we should start in the most populated countries of the world," Di Martino.
Lee’s Pharmaceutical CEO Dr Benjamin Li said Vitamin D deficiency is a growing problem, especially in patients on dialysis.
"The availability of Cholecalciferol will certainly strengthen Lee’s’ presence in the dialysis area where the Group’s leading product has been helping the improvement of quality of life of dialysis patient," Li said.
Abiogen is focused on bone metabolism and some rare diseases and is recognized as a reference in vitamin D market with Dibase (Italy) and Thorens (international).